bibliographicCitation |
Salih J, Hilpert J, Placke T, Grünebach F, Steinle A, Salih HR, Krusch M. The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. Int J Cancer. 2010 Nov 01;127(9):2119–28. doi: 10.1002/ijc.25233. PMID: 20143399. |